Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Result of AGM
The results of the Ordinary General Meeting are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:
1) Approval of the Company's individual | For | 5,065,803 | Adopted | 87,8432% | ||
financial statements for the year ended 31 | ||||||
Against | 701,067 | |||||
December 2022 (Resolution No. 1), | ||||||
Abstention | 155,203 | |||||
2) Approval of the Company's consolidated | For | 5,065,803 | Adopted | 87,8432% | ||
financial statements for the year ended 31 | ||||||
Against | 701,067 | |||||
December 2021 (Resolution No. 2), | ||||||
Abstention | 155,203 | |||||
3) Allocation of the Company's loss for the | For | 5,039,278 | Adopted | 87,1800% | ||
year ended 31 December 2021 (Resolution | ||||||
Against | 741,039 | |||||
No. 3), | ||||||
Abstention | 141,756 | |||||
4) | Authorization of the related parties | For | 5, 046,981 | Adopted | 87,4778% | |
agreements referred to in Articles L. 225-38 | ||||||
Against | 722,464 | |||||
et | seq. of the French | Commercial Code | ||||
Abstention | 152,628 | |||||
(Resolution No. 4), | ||||||
5) | Discharge to the | Board of Directors | For | 3,946,733 | Adopted | 67,6976% |
(Resolution No. 5), | ||||||
Against | 1,883,213 | |||||
Abstention | 92,127 | |||||
6) Authorisation for the Company to buy | For | 4,114,970 | Adopted | 69,9598% | ||
back its own shares (Resolution No. 6), | ||||||
Against | 1,766,940 | |||||
Abstention | 40,163 | |||||
7) Ratification of the appointment of a | For | 4,611,646 | Adopted | 79,5069% | ||
non-voting member (censeur) of the Board | ||||||
Against | 1,188,665 | |||||
of Directors (Resolution No. 7), | ||||||
Abstention | 121,762 | |||||
8) Ratification of the appointment of a | For | 4,819,353 | Adopted | 82,9845% | ||
non-voting member (censeur) of the Board | ||||||
Against | 988,178 | |||||
of Directors (Resolution No. 8), | ||||||
Abstention | 114,542 | |||||
9) Appointment of a member of the Board | For | 4,546,913 | Adopted | 78,1769% | ||
of Directors (Resolution No. 9), | ||||||
Against | 1,269,269 | |||||
Abstention | 105,891 | |||||
10) Appointment of a member of the Board | For | 4,839,961 | Adopted | 83,2870% | ||
of Directors (Resolution No. 10), | ||||||
Against | 971,221 | |||||
Abstention | 110,891 | |||||
11) Reappointment of a board member | For | 4,614,828 | Adopted | 79,8748% | ||
(Resolution No. 11), | ||||||
Against | 1,162,751 | |||||
Abstention | 144,494 | |||||
12) Reappointment of a board member | For | 4,692,570 | Adopted | 81,2944% | ||
(Resolution No. 12), | ||||||
Against | 1,079,747 | |||||
Abstention | 149,756 | |||||
13) Powers for formalities (Resolution | For | 4,993,420 | Adopted | 85,1472% | ||
No. 13), | ||||||
Against | 871,033 | |||||
Abstention | 57,620 | |||||
Number of participating shareholders (by voting form, electronic vote, proxy or present): 639 shareholders representing 5,922,073 shares.
Contacts | |
Novacyt SA | +44 (0)23 8074 8830 |
James Wakefield, Non-Executive Chairman | |
James McCarthy, Acting Chief Executive Officer | |
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 |
Matthew Johnson / Charlie Bouverat (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Deutsche Numis (Joint Broker) | +44 (0)20 7260 1000 |
Freddie Barnfield / Duncan Monteith / Michael Palser | |
Allegra Finance (French Listing Sponsor) | +33 (1) 42 22 10 10 |
Rémi Durgetto / Yannick Petit | r.durgetto@allegrafinance.com/ |
y.petit@allegrafinance.com | |
Walbrook PR (Financial PR & IR) | +44 (0)20 7933 8780 |
Stephanie Cuthbert / Anna Dunphy / Phillip Marriage | novacyt@walbrookpr.com |
About Novacyt Group
Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.
The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non- invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.
Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Novacyt SA published this content on 30 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 October 2023 17:43:35 UTC.